Evolus, Inc. (EOLS) stock
EOLSNasdaqPharmaceutical PreparationsFiscal year ends December 31
$7.00−0.07 (-0.99%)
Close on Nov 19, 2026Market cap $462.35MP/E –Yield –
Evolus shares outstanding
Diluted shares outstanding: the weighted share count used for earnings per share, adjusted for stock splits.
Evolus's shares outstanding was 66M at Jun 30, 2026. For fiscal 2025 it was 64M, up 4.0% from the year before. The highest annual figure on record is 64M in fiscal 2025.
Annual shares outstanding
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 64M | +4.0% |
| FY2024 | Dec 31, 2024 | 62M | +9.0% |
| FY2023 | Dec 31, 2023 | 57M | +1.5% |
| FY2022 | Dec 31, 2022 | 56M | +12.6% |
| FY2021 | Dec 31, 2021 | 50M | +47.5% |
| FY2020 | Dec 31, 2020 | 34M | +19.5% |
| FY2019 | Dec 31, 2019 | 28M | +15.7% |
| FY2018 | Dec 31, 2018 | 24M | +47.7% |
| FY2017 | Dec 31, 2017 | 17M | – |
Quarterly shares outstanding
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | 66M | +2.2% |
| Q1 FY2026 | Mar 31, 2026 | 65M | +2.3% |
| Q4 FY2025 | Dec 31, 2025 | 65M | +2.4% |
| Q3 FY2025 | Sep 30, 2025 | 65M | +2.5% |
| Q2 FY2025 | Jun 30, 2025 | 65M | +2.9% |
| Q1 FY2025 | Mar 31, 2025 | 64M | +8.3% |
| Q4 FY2024 | Dec 31, 2024 | 63M | +10.7% |
| Q3 FY2024 | Sep 30, 2024 | 63M | +10.7% |
| Q2 FY2024 | Jun 30, 2024 | 63M | +10.2% |
| Q1 FY2024 | Mar 31, 2024 | 59M | +4.1% |
| Q4 FY2023 | Dec 31, 2023 | 57M | +1.7% |
| Q3 FY2023 | Sep 30, 2023 | 57M | +1.5% |
| Q2 FY2023 | Jun 30, 2023 | 57M | +1.5% |
| Q1 FY2023 | Mar 31, 2023 | 56M | +1.3% |
| Q4 FY2022 | Dec 31, 2022 | 56M | +1.1% |
| Q3 FY2022 | Sep 30, 2022 | 56M | +2.1% |
| Q2 FY2022 | Jun 30, 2022 | 56M | +9.6% |
| Q1 FY2022 | Mar 31, 2022 | 56M | +35.6% |
| Q4 FY2021 | Dec 31, 2021 | 56M | +64.9% |
| Q3 FY2021 | Sep 30, 2021 | 55M | +63.0% |
| Q2 FY2021 | Jun 30, 2021 | 51M | +51.6% |
| Q1 FY2021 | Mar 31, 2021 | 41M | +21.9% |
| Q4 FY2020 | Dec 31, 2020 | 34M | +9.8% |
| Q3 FY2020 | Sep 30, 2020 | 34M | +22.9% |
| Q2 FY2020 | Jun 30, 2020 | 34M | +23.1% |
| Q1 FY2020 | Mar 31, 2020 | 34M | +23.4% |
| Q4 FY2019 | Dec 31, 2019 | 31M | +12.4% |
| Q3 FY2019 | Sep 30, 2019 | 27M | +10.9% |
| Q2 FY2019 | Jun 30, 2019 | 27M | +15.7% |
| Q1 FY2019 | Mar 31, 2019 | 27M | +35.1% |
| Q4 FY2018 | Dec 31, 2018 | 27M | +65.5% |
| Q3 FY2018 | Sep 30, 2018 | 25M | +49.9% |
| Q2 FY2018 | Jun 30, 2018 | 24M | +43.3% |
| Q1 FY2018 | Mar 31, 2018 | 20M | +22.4% |
| Q4 FY2017 | Dec 31, 2017 | 17M | – |
| Q3 FY2017 | Sep 30, 2017 | 17M | – |
| Q2 FY2017 | Jun 30, 2017 | 17M | – |
| Q1 FY2017 | Mar 31, 2017 | 17M | – |
See a number that looks wrong?